World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
93
Citations
38109
World Ranking
10761
National Ranking
5535

Philippe Armand publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Philippe Armand sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 444 publications — 48th percentile

48% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Philippe Armand D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Philippe Armand sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 93 D-Index — 47th percentile

47% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Philippe Armand is affiliated with Harvard University in the United States and has contributed extensively to the field of medicine, with particular focus on oncology, pathology, immunology, genetics, and neurology. Their work is documented through numerous publications that emphasize lymphoma diagnosis and treatment, cancer immunotherapy, CAR-T cell therapy research, and chronic lymphocytic leukemia research among other topics.

Armand's main fields of study include:

  • Medicine

The subfields they have contributed to encompass:

  • Oncology
  • Pathology and Forensic Medicine
  • Genetics
  • Immunology
  • Neurology

Major research topics covered in their publications include:

  • Lymphoma Diagnosis and Treatment
  • CAR-T cell therapy research
  • Cancer Immunotherapy and Biomarkers
  • Chronic Lymphocytic Leukemia Research
  • CNS Lymphoma Diagnosis and Treatment
  • Immune Cell Function and Interaction
  • Viral-associated cancers and disorders

Recent papers authored or co-authored by Armand feature notable work such as:

  • "NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020" (2020), published in Journal of the National Comprehensive Cancer Network
  • "Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology" (2022), published in Journal of the National Comprehensive Cancer Network
  • "Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity" (2020), published in Journal of Clinical Oncology
  • "Hodgkin Lymphoma, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology" (2020), published in Journal of the National Comprehensive Cancer Network
  • "Atorvastatin for Anthracycline-Associated Cardiac Dysfunction" (2023), published in JAMA

Frequent collaborators throughout these research efforts include:

  • Caron A. Jacobson
  • Reid W. Merryman
  • Robert Redd
  • Jennifer L. Crombie
  • Alex F. Herrera

Philippe Armand's publications appear predominantly in these venues:

  • Blood
  • Blood Advances
  • Hematological Oncology
  • Journal of Clinical Oncology
  • Leukemia & lymphoma/Leukemia and lymphoma

Best Publications

  • PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

    Stephen M. Ansell;Alexander M. Lesokhin;Alexander M. Lesokhin;Ivan Borrello;Ahmad Halwani

  • Interleukin-2 and Regulatory T Cells in Graft-versus-Host Disease

    John Koreth;Ken Ichi Matsuoka;Haesook T. Kim;Sean M. McDonough

  • Nivolumab in patients with relapsed or refractory hematologic malignancy: Preliminary results of a phase ib study

    Alexander M. Lesokhin;Alexander M. Lesokhin;Stephen M. Ansell;Philippe Armand;Emma C. Scott

  • Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma.

    Robert Chen;Pier Luigi Zinzani;Michelle A. Fanale;Philippe Armand

  • Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial

    Anas Younes;Armando Santoro;Margaret Shipp;Pier Luigi Zinzani

  • Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation

    Philippe Armand;Haesook T. Kim;Brent R. Logan;Zhiwei Wang

  • Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial.

    Philippe Armand;Andreas Engert;Anas Younes;Michelle A Fanale

  • PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome

    Margaretha G.M. Roemer;Ranjana H. Advani;Azra H. Ligon;Yasodha Natkunam

  • Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure

    Philippe Armand;Margaret A. Shipp;Vincent Ribrag;Jean Marie Michot

  • Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia

    Stefan O. Ciurea;Mei Jie Zhang;Andrea A. Bacigalupo;Asad Bashey

  • Ipilimumab for Patients with Relapse after Allogeneic Transplantation

    Matthew S. Davids;Haesook T. Kim;Pavan Bachireddy;Caitlin Costello

  • Management of Immunotherapy-Related Toxicities, Version 1.2019.

    John A. Thompson;Bryan J. Schneider;Julie Brahmer;Stephanie Andrews

  • Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II Trial

    Philippe Armand;Arnon Nagler;Edie A. Weller;Steven M. Devine

  • Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation

    Philippe Armand;Haesook T. Kim;Corey S. Cutler;Vincent T. Ho

  • Low-Dose Interleukin-2 Therapy Restores Regulatory T Cell Homeostasis in Patients with Chronic Graft-Versus-Host Disease

    Ken-ichi Matsuoka;John Koreth;Haesook T. Kim;O. Gregory Bascug

  • Antiretroviral-Free HIV-1 Remission and Viral Rebound After Allogeneic Stem Cell Transplantation: Report of 2 Cases

    Timothy J. Henrich;Emily Hanhauser;Francisco M. Marty;Michael N. Sirignano

  • PD-1 Inhibitor–Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course

    Mizuki Nishino;Nikhil H. Ramaiya;Mark M. Awad;Lynette M. Sholl

  • Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy.

    Bruce D. Cheson;Stephen Ansell;Larry Schwartz;Leo I. Gordon

  • Somatic Mutations Predict Poor Outcome in Patients With Myelodysplastic Syndrome After Hematopoietic Stem-Cell Transplantation

    Rafael Bejar;Kristen E. Stevenson;Bennett Caughey;R. Coleman Lindsley

  • PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma

    Lakshmi Nayak;Lakshmi Nayak;Fabio M. Iwamoto;Ann LaCasce;Ann LaCasce;Srinivasan Mukundan;Srinivasan Mukundan

Frequent Co-Authors

Robert J. Soiffer
Robert J. Soiffer Harvard University
Joseph H. Antin
Joseph H. Antin Dana-Farber Cancer Institute
Vincent T. Ho
Vincent T. Ho Harvard University
Corey Cutler
Corey Cutler Harvard University
Edwin P. Alyea
Edwin P. Alyea Harvard University
John Koreth
John Koreth Harvard University
Haesook T. Kim
Haesook T. Kim Harvard University
Jerome Ritz
Jerome Ritz Harvard University
Scott J. Rodig
Scott J. Rodig Harvard University
Margaret A. Shipp
Margaret A. Shipp Harvard University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring online healthcare degrees opens diverse routes for advancing your career. If you’re seeking flexibility and credibility, it’s important to consider which online healthcare degree programs are recognized for their accreditation by cahme? Accreditation ensures your qualification is respected by employers and licensing bodies.

For registered nurses looking to advance, you might wonder, does rn to bsn require clinicals? Many top RN to BSN programs now offer non-clinical pathways, providing a convenient option for working professionals who need flexibility.

Nurses aiming for the highest level of clinical practice may be interested in the shortest msn to dnp program options available online. These accelerated tracks can help you reach your Doctor of Nursing Practice with less time away from work.

If you are balancing work and study, discovering the easiest dnp programs may help you find the right fit. Streamlined curricula can make this advanced degree more accessible, supporting your journey in healthcare leadership.

Best Scientists Citing Philippe Armand

Trending Scientists

Recently Published Articles